First patients enrolled in clinical studies in bNHL and AML ABECMA generated $56M U.S. commercial revenue in 1Q; continues to track toward upper end of $250-$300M U.S. ABECMA revenue guidance for 2022 Ended quarter with $452.5M cash, cash equivalents, and marketable securities; anticipated cash
bbT369, 2seventy bio’s investigational novel CD79a/CD20 dual targeting CBLB gene edited CAR T cell therapy demonstrates promising anti-lymphoma activity in preclinical models bbT369 is the first novel cell therapy investigated in the clinic that uses 2seventy bio’s proprietary highly specific
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the CG Horizons in Oncology Virtual Conference , on the Attacking AML: New Approaches Panel on Thursday, April 14, 2022 at 1:30pm ET .
Closed $170M private placement with leading healthcare investors ABECMA generated $158M U.S. commercial revenue in 2021; tracking toward upper end of $250-300M U.S. revenue guidance for 2022 Internal cost reduction measures reduce net cash spend guidance to $190-220M for 2022 Cash runway into
Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2022-- 2seventy bio, Inc .
Steven Bernstein , M.D. appointed to chief medical officer Susan Abu-Absi , Ph.D. promoted to chief technology & manufacturing officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein , M.D.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022 , at 2:20pm ET Cowen Virtual
ABECMA generated approximately $150M U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M U.S. revenue bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of two new INDs
Collaboration further validates 2seventy bio’s megaTAL ™ gene editing platform with potential applicability across company’s oncology pipeline 2seventy bio is eligible to receive $40M in near-term payments, in addition to future milestone payments and sales royalties 2seventy bio and Genevant